-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanjing Leads Biolabs Doses First Patient in Phase Ib/II Trial of LBL-024 for Platinum-Resistant Ovarian Cancer

路透·12/23/2025 08:31:14

登录查看新闻详情